Most warning letters never close

A warning letter is the record everyone reads. Whether the problem behind it ever actually got fixed is a second, separate record — one FDA only sometimes writes, and reading a warning letter database as though its absence means the same thing every time is a mistake worth naming directly.

What a close-out letter actually certifies

FDA’s close-out letter program, which applies to warning letters issued on or after September 1, 2009, is not a formality that follows automatically once a firm claims to have fixed something. FDA’s own guidance on the program is explicit: a close-out letter will not issue on the strength of a firm’s representation that corrective action has been or will be taken. The correction has to be verified — usually through a follow-up inspection confirming the fix actually happened, occasionally through a written response FDA judges sufficient on its own. Either way, a close-out letter is FDA stating a specific, checked fact: we looked again, and this is resolved. It is not FDA taking the firm’s word for it.

The letters that were never going to get one

Two categories of warning letter are excluded from the close-out program by design, not by delay. If the violations in a warning letter are not correctable by their nature, no close-out letter will ever issue — there is nothing for a reinspection to confirm. And if the recipient is verified to be out of business, the same is true for a different reason: there is no firm left to reinspect. Both are permanent, structural absences. A reader who checks a warning letter years later and finds no close-out letter has learned nothing yet about which of several very different situations they are looking at.

What silence actually means here

That ambiguity is the practice point. No close-out letter on a given warning letter is consistent with at least four different states: the firm hasn’t fixed the problem, the firm has fixed it but FDA hasn’t reinspected to confirm it yet, the violation was structurally uncorrectable from day one, or the firm is no longer operating. FDA’s database does not distinguish between them for you — it simply doesn’t show a close-out letter in any of the four cases, and reading the field as “still open” collapses four different facts into one, incorrectly, in exactly the direction that makes a firm look worse than the record actually supports.

The practice, stated plainly

Checking whether a firm resolved a warning letter is therefore not a lookup, and building a supplier or predicate-landscape assessment on the presence or absence of a close-out letter alone will mislead you in both directions. Read the letter’s own subject and violation content first — whether the finding is the kind FDA would ever formally close out at all. Then check whether enough time has actually passed for a reinspection to plausibly have happened; a warning letter from eight months ago and one from eight weeks ago are not at the same point in the process, whatever their close-out status shows today. Absence of a close-out letter is not a finding on its own. It is the starting point for asking which of several explanations applies to the specific firm in front of you.

Whether an open or closed status changes what a specific warning letter means for a specific supplier, competitor, or predicate is, as with the rest of this record, a judgment for whoever is making that call on their own facts — this is a description of what the record does and doesn’t certify, never advice about what to conclude from one. FDA Radar ingests CDRH warning letters with their issue date, posted date, and violation themes as structured facts; close-out status today is not one of the fields it carries, which is exactly why the check above is worth doing by hand rather than assumed away.